NASDAQ:ONVOOrganovo Stock Price, Forecast & News

$0.61

-0.09 (-12.82 %)

(As of 05/27/2020 04:00 PM ET)

Add

Compare

Today's Range

$0.60

Now: $0.61▼

$0.72

50-Day Range

$0.26

MA: $0.46▼

$0.89

52-Week Range

$0.19

Now: $0.61▼

$1.05

Volume2.15 million shs

Average Volume1.08 million shs

Market Capitalization$79.86 million

P/E RatioN/A

Dividend YieldN/A

Beta1.02

Organovo Holdings, Inc., a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat a range of rare, life-threatening diseases. In addition, the company offers preclinical in vitro disease modeling platforms, including a range of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis conditions. Further, it involved in various programs to develop its NovoTissues transplantable tissues to address various serious unmet medical needs in adult and pediatric populations primarily focusing on liver disease. The company was founded in 2007 and is headquartered in San Diego, California.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Organovo.

2.5 Community Rank

Outperform Votes
Organovo has received 192 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Organovo has received 190 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Organovo has received 50.26% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Organovo and other stocks. Vote “Outperform” if you believe ONVO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ONVO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Organovo does not currently pay a dividend.
Dividend Growth
Organovo does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Organovo insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.20% of the stock of Organovo is held by insiders.
Percentage Held by Institutions
50.16% of the stock of Organovo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Organovo is -3.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Organovo is -3.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Organovo has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.70 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ONVO

Previous Symbol

CUSIPN/A

CIK1497253

Webwww.organovo.com

Phone858-224-1000

Debt

Debt-to-Equity RatioN/A

Current Ratio13.19

Quick Ratio13.19

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$3.09 million

Price / Sales25.85

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.30 per share

Price / Book2.04

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-26,640,000.00

Net Margins-798.68%

Return on Equity-69.36%

Return on Assets-59.99%

Miscellaneous

Employees70

Outstanding Shares130,498,000

Market Cap$79.86 million

Next Earnings Date6/1/2020 (Estimated)

OptionableOptionable

Receive ONVO News and Ratings via Email

Sign-up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.

Organovo (NASDAQ:ONVO) Frequently Asked Questions

How has Organovo's stock been impacted by COVID-19 (Coronavirus)?

Organovo's stock was trading at $0.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ONVO stock has increased by 135.4% and is now trading at $0.6120. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Organovo?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Organovo.

When is Organovo's next earnings date?

Organovo is scheduled to release its next quarterly earnings announcement on Monday, June 1st 2020. View our earnings forecast for Organovo.

How were Organovo's earnings last quarter?

Organovo Holdings Inc (NASDAQ:ONVO) posted its quarterly earnings results on Thursday, August, 8th. The medical research company reported ($0.05) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.05). The medical research company had revenue of $0.67 million for the quarter, compared to analysts' expectations of $0.77 million. Organovo had a negative net margin of 798.68% and a negative return on equity of 69.36%. View Organovo's earnings history.

Has Organovo been receiving favorable news coverage?

News headlines about ONVO stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Organovo earned a media sentiment score of 1.4 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutOrganovo.

Are investors shorting Organovo?

Organovo saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 3,370,000 shares, an increase of 19.9% from the April 30th total of 2,810,000 shares. Based on an average daily volume of 779,500 shares, the days-to-cover ratio is currently 4.3 days. Currently, 2.6% of the shares of the stock are short sold. View Organovo's Current Options Chain.

Who are some of Organovo's key competitors?

Some companies that are related to Organovo include Eiger Biopharmaceuticals (EIGR), Cellular Biomedicine Group (CBMG), CASI Pharmaceuticals (CASI), Tcr2 Therapeutics (TCRR), ADMA Biologics (ADMA), Gritstone Oncology (GRTS), Verona Pharma (TARA), Sutro Biopharma (STRO), Vaxart (VXRT), Axcella Health (AXLA), Pluristem Therapeutics (PSTI), GENFIT S A/ADR (GNFT), Brainstorm Cell Therapeutics (BCLI), Fennec Pharmaceuticals (FENC) and Jounce Therapeutics (JNCE). View all competitors.

What other stocks do shareholders of Organovo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone Group (BX), LADENBURG THALM/SH SH (LTS), Novavax (NVAX), Exelixis (EXEL), Anavex Life Sciences (AVXL), Micron Technology (MU) and Advanced Micro Devices (AMD).

Who are Organovo's key executives?

Organovo's management team includes the following people:

Mr. Taylor J. Crouch, CEO, Pres & Director (Age 59)
Mr. Craig Kussman, Chief Financial Officer (Age 60)
Ms. Jennifer Kinsbruner Bush, Sr. VP, Compliance Officer, Gen. Counsel & Corp. Sec. (Age 44)
Mr. Paul Gallant, Gen. Mang. (Age 54)
Mr. Steve E. Kunszabo, VP of Investor Relations & Corp. Communications

What is Organovo's stock symbol?

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

Who are Organovo's major shareholders?

Organovo's stock is owned by a variety of institutional and retail investors. Top institutional investors include WINTON GROUP Ltd (0.24%) and Advisor Group Holdings Inc. (0.07%). View institutional ownership trends for Organovo.

Which major investors are selling Organovo stock?

ONVO stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd. View insider buying and selling activity for Organovo.

Which major investors are buying Organovo stock?

ONVO stock was acquired by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc.. View insider buying and selling activity for Organovo.

How do I buy shares of Organovo?

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Organovo's stock price today?

One share of ONVO stock can currently be purchased for approximately $0.61.

How big of a company is Organovo?

Organovo has a market capitalization of $79.86 million and generates $3.09 million in revenue each year. Organovo employs 70 workers across the globe.

What is Organovo's official website?

The official website for Organovo is www.organovo.com.

How can I contact Organovo?

Organovo's mailing address is 440 STEVENS AVE SUITE 200, SOLANA BEACH CA, 92075. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff